Business
Research Published on Adjuvant Systems
Research Published on Adjuvant Systems.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1209Y Allergy Therapeutics PLC 07 May 2019 \n\n \n \n \nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Group\")\n \nAllergy Therapeutics Publishes New Research Exploring Potential of its Adjuvant Systems in the Treatment of Cancer in the Journal of ImmunoTherapy of Cancer\n \n- Research illustrates broad, novel applications of the Group's adjuvant systems portfolio beyond allergy indications -\n \n7 May 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces, through its adjuvant research division Bencard Adjuvant Systems, the publication of new research into the Group's adjuvant system Microcrystalline Tyrosine (MCT®) combined with Virus-Like particles (VLPs). \n \nThe research, Vaccination with nanoparticles combined with micro-adjuvants protects against cancer (Mohsen M et al.), undertaken by the Group's adjuvant research division, Bencard Adjuvant Systems and published in the Journal for ImmunoTherapy of Cancer, investigated the protective efficacy of the Group's adjuvant system against cancer and showed that the combination of MCT and VLPs caused tumour regression in an aggressive melanoma mouse model and initiated a highly protective CD8 T-cell immune response.\n \nManuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: \"Our strategy for growth with our adjuvant division, Bencard Adjuvant Systems, focuses on extending the use of MCT® and VLPs in developing vaccines for unmet needs and disease areas beyond allergy that require an effective depot adjuvant. This ground-breaking work, completed in collaboration with the Jenner Institute at the University of Oxford, supports this strategy and complements the existing work illustrating the potential of our adjuvant systems in disease areas such as influenza and malaria.\" \n \nAbout the study: Microcrystalline Tyrosine and Virus-Like Particles in treating cancer\nThe paper was published in conjunction with collaborators from the Jenner Institute, Oxford, UK and University of Bern, Switzerland and describes how the depot effect of MCT allows release of VLP-antigen to reach lymphoid organs efficiently (<72hrs) for optimal priming of T-cells. \n \nThe induction of strong T...